NextCure announced 55% objective response rate for SIM0505 in gynecologic cancers at ASCO 2026, with favorable safety in heavily pretreated patients. The data supports continued dose optimization and potential advancement toward pivotal trials for this CDH6-targeting antibody drug conjugate.